KMDA — Kamada Ltd. stock price, charts and financials

NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·IL

Latest market price

8.85

+0.18+2.08%

Overview Short InterestFilings

KMDAQT69Kamada Ltd.·NASDAQ

Overview Short InterestFilings

8.85+2.08%

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

EOLS-1.87%$7.86 EVO-4.19%$1.60 AQST-1.07%$4.61 TLRY+1.27%$3.99 CGC-0.50%$0.93 IRWD+3.07%$4.36 COLL+1.74%$22.77 EBS-3.13%$6.80

Snapshot

Index	-	P/E	23.29	EPS (ttm)	0.38	Insider Own	1.93%	Shs Outstand	57.69M	Perf Week	11.74%

Market Cap	510.59M	Forward P/E	14.83	EPS next Y	0.60	Insider Trans	-17.95%	Shs Float	31.45M	Perf Month	12.17%

Enterprise Value	450.59M	PEG	1.29	EPS next Q	0.14	Inst Own	-	Short Float	0.50%	Perf Quarter	21.07%

Income	22.00M	P/S	2.66	EPS this Y	28.29%	Inst Trans	-	Short Ratio	1.99	Perf Half Y	2.67%

Sales	192.00M	P/B	1.89	EPS next Y	22.39%	ROA	5.81%	Short Interest	156.78K	Perf YTD	25.35%

Book/sh	4.68	P/C	7.29	EPS next 5Y	18.00%	ROE	8.37%	52W High	9.35 -5.35%	Perf Year	28.26%

Cash/sh	1.21	P/FCF	17.25	EPS past 3/5Y	- -2.03%	ROIC	6.90%	52W Low	6.50 36.15%	Perf 3Y	71.84%

Dividend Est.	0.17 (1.92%)	EV/EBITDA	10.99	Sales past 3/5Y	11.74% 6.24%	Gross Margin	40.82%	Volatility	3.00% 2.70%	Perf 5Y	66.67%

Dividend TTM	0.42 (4.75%)	EV/Sales	2.35	EPS Y/Y TTM	52.00%	Oper. Margin	14.51%	ATR (14)	0.27	Perf 10Y	80.98%

Dividend Ex-Date	Aug 27, 2026	Quick Ratio	2.29	Sales Y/Y TTM	19.25%	Profit Margin	11.60%	RSI (14)	65.44	Recom	2.17

Dividend Gr. 3/5Y	-	Current Ratio	4.06	EPS Q/Q	23.08%	SMA20	6.26%	Beta	0.89	Target Price	15.00

Payout	63.73%	Debt/Eq	0.04	Sales Q/Q	22.22%	SMA50	15.35%	Rel Volume	1.69	Prev Close	8.67

Employees	462	LT Debt/Eq	0.03	Earnings	Nov 09	SMA200	12.10%	Avg Volume	105.45K	Price	8.85

IPO Date	May 31, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	42.22% 8.03%	Net Debt/EBITDA	-0.42	Volume	178,118	Change	2.08%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Sep-18-26	Reiterated	UBS		$15
Jul-21-26	Reiterated	William Blair		$15
Mar-11-26	Reiterated	Stifel Nicolaus		$20 → $11
Dec-09-25	Reiterated	HC Wainwright & Co.	Buy	$13
Nov-13-24	Reiterated	Stifel Nicolaus		$20

Latest News· Times ET

Sep-17-26

Sep-17-2603:00AM

CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demandglobenewswire.com

Sep-10-26

Sep-10-2603:00AM

Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conferenceglobenewswire.com

Sep-08-26

Sep-08-2607:02AM

Director At Kamada Exercises Options Worth $77KBenzinga

Sep-03-26

Sep-03-2612:01PM

Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholdersglobenewswire.com

Sep-01-26

Sep-01-2601:00AM

AI Exhaustion? 3 Healthcare Stocks With 38% EPS Growth That Could Be The CureSeekingAlpha

Aug-17-26

Aug-17-2603:00AM

Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026globenewswire.com

Aug-14-26

Aug-14-2609:45AM

Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"zacks.com

08:41AM

KMDA or PRTA: Which Is the Better Value Stock Right Now?zacks.com

06:56AM

Wall Street Analysts Think Kamada (KMDA) Could Surge 79.06%: Read This Before Placing a Betzacks.com

Aug-12-26

Aug-12-2607:47AM

Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcriptseekingalpha.com

06:31AM

Kamada (KMDA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimateszacks.com

05:26AM

Kamada (KMDA) Q2 Earnings and Revenues Surpass Estimateszacks.com

03:05AM

Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidanceglobenewswire.com

03:00AM

Kamada Announces Planned Transition of Chief Financial Officerglobenewswire.com

Aug-06-26

Aug-06-2607:02AM

Options Exercise Update At Kamada: Lilach Payorski Engages, Resulting In $0Benzinga

Company

Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	192	180	161	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	113	104	91	—	—	—	—	—	—
Gross Profit	78	76	70	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	37	34	31	—	—	—	—	—	—
Research and Development	10	13	15	—	—	—	—	—	—
Other Operating Expense	3	3	4	—	—	—	—	—	—
Operating Income	29	26	20	—	—	—	—	—	—
Interest Expense	0	1	1	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	0	-2	-6	—	—	—	—	—	—
Net Income Before Taxes	26	23	13	—	—	—	—	—	—
Income Taxes	4	3	-1	—	—	—	—	—	—
Consolidated Net Income	22	20	14	—	—	—	—	—	—
Net Income From Continuing Operations	22	20	14	—	—	—	—	—	—
Net Income	22	20	14	—	—	—	—	—	—
EPS (Recurring)	0.38	0.38	0.25	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	0.38	0.38	0.25	—	—	—	—	—	—
EPS (Diluted)	0.38	0.37	0.25	—	—	—	—	—	—
EBITDA	41	39	28	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	23.29	19.08	24.36	—	—	—	—	—	—
Price To Sales Ratio	2.67	2.27	2.16	—	—	—	—	—	—
Gross Margin	40.63	42.22	43.48	—	—	—	—	—	—
Operating Margin	15.10	14.44	12.42	—	—	—	—	—	—
Net Margin	11.46	11.11	8.70	—	—	—	—	—	—
Shares Outstanding	58	58	57	—	—	—	—	—	—
Market Capitalization	513	409	347	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brenner Yael	VP Quality	Sep 14 '26	Option Exercise	5.93	16,964	100,597	12,766	Sep 17
Tsur David	Director	Sep 14 '26	Sale	8.18	22,827	186,725	407,929	Sep 17
Livneh Nir	VP, General Counsel	Sep 14 '26	Option Exercise	5.37	10,000	53,700	10,000	Sep 17
Tsur David	Director	Sep 09 '26	Sale	8.26	175	1,446	430,756	Sep 11
Tsur David	Director	Sep 08 '26	Sale	8.26	162,760	1,344,398	430,931	Sep 11
Tsur David	Director	Sep 07 '26	Sale	8.28	14,238	117,891	593,691	Sep 11
Tsur David	Director	Sep 02 '26	Option Exercise	6.71	49,000	328,690	634,429	Sep 08
Brenner Yael	VP Quality	Sep 02 '26	Option Exercise	5.94	3,036	18,034	9,302	Sep 08
Brenner Yael	VP Quality	Aug 26 '26	Option Exercise	6.25	10,000	62,500	16,266	Aug 31

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.